Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective real world global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice

Next Previous
X
Search
Trial Profile

A retrospective real world global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy; Generalised seizures; Seizures
  • Focus Therapeutic Use
  • Acronyms PERMIT; PERMIT

    • Most Recent Events

    • 28 Apr 2023 Results of subgroup analysis (n=544) analyzing perampanel in patients with idiopathic generalized epilepsy published in the Epilepsia.
    • 27 Apr 2023 Results of pooled analysis of PERMIT and PROVE assessing perampanel when used in everyday clinical practice, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, data from this study (to be presented in AAN 2023) is presented online https://index.mirasmart.com/aan2023/PDFfiles/AAN2023-002293.html.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top